News from Direct Biologics

Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome

Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials to address early stage COVID-19. AUSTIN, Texas, June 29, 2021 (Newswire.com) Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that the U.S Food and… Read More »Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome

The post Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome appeared first on Direct Biologics.